Beleave Plans to Develop Novel Instrumentation and Methodologies for the Rapid In Situ Quantification of Micronutrient and Heavy Metal Content Found in Cannabis Plant Material

TORONTO, ON--(Marketwired - August 01, 2017) - Beleave Inc. ("Beleave" or the "Company") (CSE: BE) (CSE: BE.CN) (CNSX: BE) is pleased to announce that it is now beginning work on a technological development research project at Ryerson University, with the goal of developing and validating technologies that are able to quantify micronutrient and heavy metal content in the cannabis plant, in real time. This project is geared to help authorized cannabis cultivators optimize their cultivation process and allow them to rapidly evaluate quality assurance metrics of finished products.

Beleave is partnering with Dr. Robert Gossage, a professor in the department of Chemistry and Biology and Dr. Eric Da Silva, an assistant professor from the Department of Physics at Ryerson University to develop portable spectroscopic instruments and non-destructive methodologies which the Company plans to use to perfect their cultivation practices. The Company and principal investigator will also be making use of the Ryerson University Analytical Center to validate their novel instrumentation and methodologies.

A $25,000 Engage grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) has been awarded to help cover some research costs for the 6-month project, which will begin today, August 1^st, 2017. All intellectual property stemming from the development of this novel technology will belong to Beleave.

About Beleave
Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). Beleave's wholly-owned subsidiary First Access Medical Inc. ("FAM") has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave's purpose-built facility is located near Hamilton, Ontario.

About Ryerson
Ryerson University is Canada's leader in innovative, career-oriented education. Urban, culturally diverse and inclusive, the university is home to more than 41,500 students, including 2,400 master's and PhD students, 3,200 faculty and staff, and nearly 170,000 alumni worldwide. For more information, visit www.ryerson.ca

About NSERC
NSERC invests over $1 billion each year in natural sciences and engineering research in Canada. Its investments deliver discoveries -- valuable world-firsts in knowledge claimed by a brain trust of over 11,000 professors. NSERC's investments enable partnerships and collaborations that connect industry with discoveries and the people behind them. Researcher-industry partnerships established by NSERC help inform R&D, solve scale-up challenges, and reduce the risks of developing high-potential technology.

NSERC also provides scholarships and hands-on training experience for more than 30,000 post-secondary students and post-doctoral fellows. These young researchers will be the next generation of science and engineering leaders in Canada.

Forward-Looking Statements

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the ability to complete the research that is currently in discussion, requirements to obtain additional funding for such research, timeliness of government approvals for granting of permits and licences, where necessary, actual results and usability from the research, regulatory or political change, competition and other risks affecting the Company in particular and the medical cannabis industry generally. Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward -looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.